companiesCompany
Corvus Pharmaceuticals
aka Corvus Pharmaceuticals, Inc., NASDAQ:CRVS
Corvus Pharmaceuticals is a Californian biotech whose oral ITK inhibitor soquelitinib rebalances T cells, with a registrational trial in relapsed T-cell lymphoma and studies in atopic dermatitis.
Overview
Corvus Pharmaceuticals develops soquelitinib (CPI-818), a selective covalent inhibitor of interleukin-2-inducible T-cell kinase (ITK) that blocks malignant T cells and steers helper T cells towards a Th1 profile. It is in a registrational phase 3 trial in relapsed peripheral T-cell lymphoma and in phase 1 trials in atopic dermatitis. The company also developed the adenosine A2A antagonist ciforadenant and the CD73 antibody mupadolimab.
Headquarters
Burlingame, California, US
Scorecard
All companies#376of 1181 companies, score 8
- phase 3 +3
- modalities +2
- registry trials +3
0 approved, 1 in phase 3, 0 earlier, 0 targets, 3 registry studies. Formula on the scorecards page.
Type
biotech · NASDAQ:CRVS
Stage
Public
Website
Founded
2014